Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided Adjuvant Chemotherapy in Stage II-III Gastric Cancer
NCT06157216Active, not recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur, oxaliplatin and capecitabine in gastric cancer (GC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: 3-year Disease-Free Survival rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
tegafuroxaliplatincapecitabine
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06157216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157216.